Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

27P - Methodology for identification of clinically relevant targets for TCR-immunotherapy in hepatocellular carcinoma

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Panagiota Maravelia

Citation

Annals of Oncology (2020) 31 (suppl_7): S1425-S1427. 10.1016/annonc/annonc390

Authors

P. Maravelia, A. Potti, D..S. Silva, T. Sekine, K. Healy

Author affiliations

  • Karolinska Institutet, Huddinge/SE
More

Abstract 27P

Background

Hepatocellular carcinoma (HCC) is a primary type of liver cancer that ranks as the fourth most leading cause of cancer-related deaths world-wide. Treatment options including ablation and chemotherapies are not always efficient to eliminate advanced HCC. Immunotherapies have general low response rates in advanced HCC patients, indicating that new approaches are needed in order to improve the current clinical responses. Our main objective is to identify mutations that can be clinically relevant targets for T cell immunotherapy in HCC patients.

Methods

Here we present data from three advanced HCC patients that underwent liver transplantation. Tumors from the explanted livers were sequenced with the Illumina Trusight Oncology 500 platform. This platform allowed us to focus on clinically relevant tumor mutations and at the same time acquire information on the patient HLA restriction, in order to perform HLA binding prediction analysis. The mutations were ranked according to their specific relevance for HCC, presence of frequent substitutions (hot-spot) and likelihood of HLA binding. The screening of the synthesized peptides and minigenes encoding the top-ranking mutations for their ability to activate T cells is ongoing.

Results

16, 13 and 7 top ranking somatic mutations were identified respectively for the three patients. Among those, we identified ‘hot-spot’ mutations in driver oncogenes such as the CTNNB1 and other highly frequent HCC associated genes including the PIK3CA, CDKN2A and KMT2C. For each frequent HLA allele such as A*01, A*02, A*03, B*07 and C*03 we identified between 4 and 12 peptides with high predicted binding affinity.

Conclusions

Based on these preliminary data from three advanced HCC samples, we identified hot-spot mutations in driver oncogenes and highly frequent HCC associated genes. We also identified potential high affinity binders for frequently expressed HLA class I alleles. These data are increasing the likelihood of identifying T cell receptors that can be used for T cell-based immunotherapy broadly in a high number of cancer patients. The immunological testing of these mutations and the identification of specific T cell receptors is still ongoing.

Legal entity responsible for the study

Karolinska Institute.

Funding

Center for Innovative Medicine and Sjöberg Foundation.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.